ClinicalTrials.gg
CompletedNCT03392363SMARTCOUGH-C-2Updated Nov 8, 2018

Diagnosing Respiratory Disease in Children Using Cough Sounds 2

An observational study in Pneumonia, Bronchiolitis and Asthma Exacerbation, sponsored by ResApp Health Limited. Completed at 3 sites in United States. Open to participants aged 29 Days to 12 Years. Per ClinicalTrials.gov, last updated 2018-11-08.

Sponsored by ResApp Health Limited · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,470
Ages
29 Days to 12 Years
Sex
All
01

Study summary

The purpose of this prospective study is to evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood acute respiratory disease, including pneumonia, bronchiolitis, asthma/reactive airways disease, croup, lower respiratory tract disease (LRTD), viral lower respiratory tract infection (vLRTI), and upper respiratory tract disease (URTD).

02

Conditions studied

  • Pneumonia
  • Bronchiolitis
  • Asthma Exacerbation
  • Croup
  • Reactive Airway Disease
  • Upper Respiratory Disease
  • Viral Lower Respiratory Tract Infections
  • Lower Respiratory Disease
03

In context

Pneumonia

1,564 studies on the registry are indexed under Pneumonia; 265 are open to participants now.

This study's enrollment of 1,470 is above the median of 252 across 535 observational studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

ResApp Health Limited is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
29 Days to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with signs or symptoms of respiratory disease presenting to participating Emergency Departments, Urgent Care Clinics, Outpatient Clinics or an Inpatient Ward within 24 hours of admission.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infant or child aged greater than 29 days up to and including their 12th birthday (infant and children pediatric subgroups as defined in Guidance for Industry and Food and Drug Administration Staff: Premarket Assessment of Pediatric Medical Devices dated March 24, 2014)
  • Presenting to the study site (an outpatient facility, an urgent care center, an Emergency Department, or inpatient ward within 24 hours of admission) with current signs or symptoms of respiratory disease including cough, wheezing, stridor, chest in-drawing/retractions, difficulty breathing, fast breathing, nasal congestion/rhinorrhea, abnormal lung sounds on exam or cyanosis/hypoxemia.
  • Onset of symptoms within past 14 days
  • Outpatient or inpatient within 24 hours of admission
  • Coughing spontaneously or able to cough voluntarily

Exclusion criteria

Exclusion Criteria:

  • Lack of a signed consent form from parent or legal guardian
  • Lack of signed assent form for children aged 7 years or older who, in the opinion of the investigator, is able to provide assent based on their age, maturity or psychological state.
  • Need for mechanical ventilatory support ((including invasive, CPAP, or BiPAP)) or high flow nasal cannula
  • History of structural airways abnormalities, tracheobronchomalacia, or vocal cord abnormalities (e.g. laryngomalacia, tracheomalacia, or bronchomalacia)
  • Any medical to voluntary cough, including the following (only enroll if coughing spontaneously): severe respiratory distress, history of pneumothorax, eye/chest/abdominal surgery in past 3 months, hemoptysis in the past month
  • Too medically unstable to participate in study per treating clinician
  • Subject previously enrolled in SMARTCOUGH-C-2 study
  • Tracheostomy present or tube placed
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,470 participants (actual)
Patient registry
No

Interventions

  • DeviceRecordings of Infants and Children's Cough Sounds

    Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease.

06

What researchers measure

Primary outcomes

  1. Diagnosis of pneumonia

    Positive percent agreement and negative percent agreement to diagnose and rule out pneumonia as compared with (1) World Health Organization (WHO) Primary Endpoint Pneumonia (PEP) plus clinical pneumonia, (2) WHO PEP or Other Infiltrate plus clinical pneumonia, (3) Clinical pneumonia alone

    Time frame: 6 months

  2. Diagnosis of other childhood respiratory diseases

    Positive percent agreement and negative percent agreement to diagnose and rule out: lower respiratory tract disease (i.e. respiratory condition occurring below the level of the larynx), viral lower respiratory tract infection, bronchiolitis, asthma/reactive airways disease, upper respiratory tract disease, and croup.

    Time frame: 6 months

07

Study locations

3 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Cleveland Clinic Children's
    Cleveland, Ohio 44195, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03392363
Lead sponsor
ResApp Health Limited
Collaborators
Massachusetts General Hospital, The Cleveland Clinic, Baylor College of Medicine, Baim Institute for Clinical Research
Responsible party
Sponsor
First posted
Jan 5, 2018
Start date
Jan 5, 2018
Primary completion
Oct 19, 2018
Completion
Oct 19, 2018
Last update
Nov 8, 2018

Study contacts

Peter P Moschovis, MD, MPH
principal investigator · Massachusetts General Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion